Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade-Reference-Cited by-同舟云学术

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade

Published:2023-05 Issue:3 Volume:24 Page:e152-e159
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Navani Vishal^ORCID,Meyers Daniel E.,Ruan Yibing,Boyne Devon J.,O'Sullivan Dylan E.,Dolter Samantha,Grosjean Heidi AI,Stukalin Igor,Heng Daniel Y.C.,Morris Don G.,Brenner Darren R.,Sangha Randeep,Cheung Winson Y.,Pabani Aliyah

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung Cancer With PD-L1 tumor proportion score >/= 50;Reck;J Clin Oncol,2021

2. Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung Cancer;Borghaei;J Clin Oncol,2021

3. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials;Gan;Eur J Cancer,2021

4. The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors;Meyers;Cancers (Basel),2019

5. Effectiveness and safety of first-line Pembrolizumab in older adults with PD-L1 positive non-small cell lung cancer: a retrospective cohort study of the alberta immunotherapy database;Grosjean;Curr Oncol,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice;Journal of Clinical Medicine;2023-03-21